Mougari, Said https://orcid.org/0000-0002-9319-5454
Favède, Valérie https://orcid.org/0000-0002-4421-1673
Predella, Camilla https://orcid.org/0000-0003-3699-0256
Reynard, Olivier https://orcid.org/0000-0001-7536-355X
Durand, Stephanie
Mazelier, Magalie https://orcid.org/0000-0002-6814-2721
Pizzioli, Edoardo https://orcid.org/0000-0002-9373-4657
Decimo, Didier https://orcid.org/0000-0002-0390-1205
Bovier, Francesca T.
Lapsley, Lauren M.
Castagna, Candace https://orcid.org/0000-0003-2410-9361
Lieberman, Nicole A. P. https://orcid.org/0000-0001-9334-8150
Noel, Guillaume
Mathieu, Cyrille https://orcid.org/0000-0002-6682-2029
Malissen, Bernard
Briese, Thomas https://orcid.org/0000-0002-4819-8963
Greninger, Alexander L. https://orcid.org/0000-0002-7443-0527
Alabi, Christopher A. https://orcid.org/0000-0003-2654-018X
Dorrello, N. Valerio
Marot, Stéphane https://orcid.org/0000-0003-4438-5793
Marcelin, Anne-Geneviève https://orcid.org/0000-0003-4808-8999
Zarubica, Ana
Moscona, Anne https://orcid.org/0000-0002-1796-8320
Porotto, Matteo https://orcid.org/0000-0003-3866-9220
Horvat, Branka https://orcid.org/0000-0003-0578-7765
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-20-COVI-000)
Foundation for the National Institutes of Health (RO1 AI160961, RO1 AI160953)
Article History
Received: 25 July 2024
Accepted: 8 January 2025
First Online: 15 January 2025
Competing interests
: M.P. and A.M. anticipate future financial interest in Thylacine Biotherapeutics, a company established to develop lipopeptide antiviral therapeutics. A.M., M.P., B.H. and C.M. are inventors of several provisional patent applications related to the use of antiviral lipopeptides.